Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| treatment group | Experimental | Tislelizumab 200mg iv D1+anlotinib(12mg D1-12) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tislelizumab | Drug | 200mg iv D1 Q3W |
| |
| Anlotinib |
| Measure | Description | Time Frame |
|---|---|---|
| objective response rate | The rate of tumor shrinkage reached 30% at least .including part reponse and complete response | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| progression free survival time | the time from initiation of treatment to disease progression or death as assessed by the treating physicians in the study (investigator-assessed). | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| linzhu zhai | Contact | 02036492550 | linzhuzhai@163.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Anlotinib 12mg D1-12 Q3W |
|
| over survival time |
the time from initiation of treatment to death as assessed by the treating physicians in the study (investigator-assessed). |
| From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to18 months |
| disease control rate | assessment of tumor the rate of the tumor harvest control including CR.PR and SD | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months |
| safety including any grade adverse events | The adverse event type and the proportion of AE during the progress of disease treatment | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months |
| ID | Term |
|---|---|
| C000707970 | tislelizumab |
| C000625192 | anlotinib |
Not provided
Not provided
Not provided